Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:47 UTC. Every row links to its source record.

Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time

A Phase 1 Study of CNTO 328 (Siltuximab) in Relapsed or Refractory Multiple Myeloma

NCT01309412 · Janssen Pharmaceutical K.K. · PHASE1 · terminated · last registry update 2014-05-19 · Multiple myeloma · Decision brief

No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.

What was said, and by whom

Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.

Kind	Quote	Our category	Source
Stated	“Protocol was stopped due to the safety issue in Global”	Open Targets' class: safety sideeffects	Registry record, Janssen Pharmaceutical K.K.

Also happening at the time. Not shown to be a cause.

Registry events on other trials of drugs against IL6 in multiple myeloma within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.

2014-11-18Results posted on the registry: Janssen Research & Development, LLC, Siltuximab11 mg/kg + Siltuximab 8.3 mg/kg or 11 mg/kg (NCT00911859)

What is not public

Internal portfolio and board discussions
Unpublished trial data and interim analyses
Terms of any partner or licence decision